<PAGE>
FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
[X] Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange
Act of 1934 For the quarterly period ended MARCH 31, 2000 or
[ ] Transition report pursuant to section 13 or 15(d) of the Securities Exchange
Act of 1934 For the transition period from to
------------- -------------
1-9731
(COMMISSION FILE NO.)
ARRHYTHMIA RESEARCH TECHNOLOGY, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 72-0925679
(STATE OR OTHER JURISDICTION OF INCORPORATION (I.R.S. EMPLOYER
OR ORGANIZATION) IDENTIFICATION NO.)
1101 SOUTH CAPITAL OF TEXAS HIGHWAY
BUILDING G - SUITE 200
AUSTIN, TEXAS 78746
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICE) (ZIP CODE)
(512) 347-9640
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes X No .
---- ----
As of May 5, 2000 there were 3,397,277 shares of common stock outstanding.
This report consists of 9 pages.
<PAGE>
ARRHYTHMIA RESEARCH TECHNOLOGY, INC.
TABLE OF CONTENTS
FORM 10-Q
March 31, 2000
<TABLE>
<S> <C> <C>
PART I - FINANCIAL INFORMATION.......................................................................................3
Item 1. Financial Statements....................................................................................3
CONSOLIDATED BALANCE SHEETS......................................................................................3
CONSOLIDATED STATEMENTS OF OPERATIONS............................................................................4
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY.......................................................5
CONSOLIDATED STATEMENTS OF CASH FLOWS............................................................................6
SUPPLEMENTAL NOTES TO CONSOLIDATED FINANCIAL STATEMENTS..........................................................7
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations..................7
PART II - OTHER INFORMATION..........................................................................................9
Item 1. Legal Proceedings.......................................................................................9
Item 2. Changes in Securities - none............................................................................9
Item 3. Defaults Upon Senior Securities - none..................................................................9
Item 4. Submission of Matters to a Vote of Security Holders - none..............................................9
Item 5. Other Information - none................................................................................9
Item 6. Exhibits and Reports on Form 8-K - none.................................................................9
SIGNATURES.......................................................................................................9
</TABLE>
2
<PAGE>
ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
(Unaudited)
<TABLE>
<CAPTION>
March 31, December 31,
ASSETS 2000 1999
------------ -----------
<S> <C> <C>
Current assets:
Cash and cash equivalents .......................................................... $ 477,506 $ 455,674
Trade and other accounts receivable, net of allowance for doubtful accounts
of $83,203 and $83,203 ....................................................... 1,605,396 1,653,098
Inventories, net ................................................................... 1,201,204 1,082,517
Income Tax Recoverable ............................................................. 329,408 329,408
Other current assets ............................................................... 75,687 52,172
----------- -----------
Total current assets ............................................................. 3,689,201 3,572,869
Property and equipment, net of accumulated depreciation of $3,888,370 and
$3,699,282 .................................................................... 3,788,250 3,835,831
Patent and software development costs, net of accumulated amortization of $482,470
and $474,712 .................................................................. 121,956 122,887
Goodwill, net of accumulated amortization of $919,076 and $886,603 ................... 1,554,250 1,586,723
Deferred Leasing Costs, net of accumulated amortization of $560 and $0 ............... 6,150 6,710
Deferred income taxes, net ........................................................... 423,923 423,923
Other assets ......................................................................... 293,232 152,743
----------- -----------
Total assets ..................................................................... $ 9,876,962 $ 9,701,686
=========== ===========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Revolving credit facilities ........................................................ $ 0 $ 0
Current maturities of bonds payable and long-term debt ............................. 723,464 711,464
Current maturities of capital lease obligations .................................... 14,757 23,811
Accounts payable ................................................................... 435,210 412,933
Accrued liabilities and Other Liabilities .......................................... 319,069 250,714
----------- -----------
Total current liabilities ........................................................ 1,492,500 1,398,922
Other long-term debt, net of current maturities ...................................... 46,815 46,815
Capital lease obligations, net of current portion .................................... 25,530 25,530
Deferred revenue ..................................................................... 6,847 8,680
----------- -----------
Total liabilities ................................................................ 1,571,692 1,479,947
----------- -----------
Shareholders' equity:
Preferred stock, $1 par value; 2,000,000 shares authorized, none issued ............ - -
Common stock, $.01 par value; 10,000,000 shares authorized; ........................
3,711,883 issued ............................................................... 37,119 37,119
Additional paid-in-capital ........................................................... 8,946,293 8,946,293
Common stock held in treasury, 307,506 and 298,406 shares at cost .................... (1,170,092) (1,151,892)
Unearned ESOP compensation ........................................................... 0 0
Retained earnings .................................................................... 491,950 390,219
----------- -----------
Total shareholders' equity ....................................................... 8,305,270 8,221,739
----------- -----------
Total liabilities and shareholders' equity ....................................... $ 9,876,962 $ 9,701,686
=========== ===========
</TABLE>
The accompanying notes are an integral part of the consolidated financial
statements.
3
<PAGE>
ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
<TABLE>
<CAPTION>
Three Months Ended March 31,
------------------------------------
2000 1999
------------- -------------
<S> <C> <C>
Net sales ............................................. $ 2,543,826 $ 2,441,683
Cost of sales ......................................... 1,676,634 1,729,094
------------- -------------
Gross profit .......................................... 867,192 712,589
------------- -------------
Selling and marketing ................................. 105,580 70,598
General and administrative ............................ 487,138 500,827
Research and development .............................. 52,927 44,860
Amortization of goodwill .............................. 32,472 33,102
------------- -------------
Total expenses ........................................ 678,117 649,387
------------- -------------
Income from operations ................................ 189,075 63,202
Other expense:
Interest expense .................................... 7,239 9,977
Other ............................................... 28,105 35,873
------------- -------------
Income before income taxes ............................ 153,731 17,352
Income taxes .......................................... 52,000 18,483
------------- -------------
Net income (loss) ..................................... $ 101,731 $ (1,131)
============= =============
Net income (loss) per share - basic ................... $ 0.03 $ 0.00
============= =============
Weighted average number of common
shares outstanding .................................. 3,405,377 3,485,001
============= =============
Net income (loss) per share - diluted ................. $ 0.03 $ 0.00
============= =============
Dillutive average number of common
equivalent shares outstanding ....................... 3,465,921 3,485,001
============= =============
</TABLE>
The accompanying notes are an integral part of the consolidated financial
statements.
4
<PAGE>
ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
<TABLE>
<CAPTION>
Retained
Additional Unearned Earnings
Common Shares Paid-in Treasury ESOP (Accumulated
Number Amount Capital Stock Compensation Deficit) Total
---------- ---------- ----------- ----------- ----------- ----------- -----------
<S> <C> <C> <C> <C> <C> <C> <C>
January 1, 1996 .............. 3,564,511 $ 36,792 $ 8,899,261 $ (868,740) $ (167,848) $ (546,718) $ 7,352,747
Exercise of options...........
Maturity and repurchases of
redeemable common stock .... 10,046 10,046
ESOP payments ................ 42,857 42,857
Treasury stock purchase ...... (1,410) (10,047) (10,047)
Net income ................... 616,578 616,578
---------- ---------- ----------- ----------- ----------- ----------- -----------
December 31, 1996 ............ 3,563,101 36,792 8,909,307 (878,787) (124,991) 69,860 8,012,181
Maturity and repurchases of
redeemable common stock.....
Treasury stock purchase.......
ESOP payments ................ 42,857 42,857
Net income ................... 31,752 31,752
---------- ---------- ----------- ----------- ----------- ----------- -----------
December 31, 1997 ............ 3,563,101 36,792 8,909,307 (878,787) (82,134) 101,612 8,086,790
Treasury stock purchase ...... (28,400) (34,297) (34,297)
ESOP payments ................ 42,857 42,857
Net income ................... (136,438) (136,438)
---------- ---------- ----------- ----------- ----------- ----------- -----------
December 31, 1998 ............ 3,534,701 36,792 8,909,307 (913,084) (39,277) (34,826) 7,958,912
Issuance of common stock ..... 32,667 327 36,986 37,313
Treasury stock purchase ...... (153,891) (238,808) (238,808)
ESOP payments ................ 39,277 39,277
Net income ................... 425,045 425,045
---------- ---------- ----------- ----------- ----------- ----------- -----------
December 31, 1999 ............ 3,413,477 37,119 8,946,293 (1,151,892) 0 390,219 8,221,739
Treasury stock purchase ...... (9,100) (18,200) (18,200)
Net income ................... 101,731 101,731
---------- ---------- ----------- ----------- ----------- ----------- -----------
March 31, 2000 ............... 3,404,377 $ 37,119 $ 8,946,293 $(1,170,092) $ 0 $ 491,950 $ 8,305,270
========== ========== =========== =========== =========== =========== ===========
</TABLE>
The accompanying notes are an integral part of the consolidated
financial statements.
5
<PAGE>
ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
<TABLE>
<CAPTION>
Three Months Ended March 31,
-------------------------
2000 1999
----------- -----------
<S> <C> <C>
Cash flows from operating activities:
Net Income (loss) .............................................................................. $ 101,731 $ (1,131)
Adjustments to reconcile net income (loss) to net cash provided by operating
activities:
Depreciation ................................................................................. 189,088 169,987
Amortization ................................................................................. 40,791 42,146
----------- -----------
Changes in assets and liabilities:
(Increase) Decrease in Trade and other accounts receivable, net .............................. 47,702 (757,947)
(Increase) Decrease in deposits, prepaid expenses and other current assets ................... (23,515) 15,217
(Increase) Decrease in Inventories ........................................................... (118,687) 474,830
Increase (Decrease) in Accounts payable, accrued liabilities and other current liabilities ... 75,303 (51,171)
Increase (Decrease) in Income taxes payable .................................................. 4,442 (61,762)
(Increase) Decrease in other assets .......................................................... 0 0
----------- -----------
Net cash provided (used) by operating activities ............................................ 316,855 (169,831)
----------- -----------
Cash flows from investing activities:
Net capital expenditures ....................................................................... (141,507) (159,266)
Deposits on capital equipment, acquisitions and other .......................................... (140,489) (3,116)
Patent and software development expenditures ................................................... (6,827) (26,365)
----------- -----------
Net cash used in investing activities ........................................................ (288,823) (188,747)
----------- -----------
Cash flows from financing activities:
Net repayments of revolving credit facilities .................................................. -- 10,000
Increase in bonds payable due to amortization .................................................. 12,000 (5,125)
Reduction of unearned ESOP compensation ........................................................ -- 10,714
Principal paid for on treasury stock ........................................................... (18,200) (30,840)
Principal payments on long-term debt, net ...................................................... -- (74,999)
----------- -----------
Net cash used in financing activities ........................................................ (6,200) (90,250)
----------- -----------
Net increase (decrease) in cash and cash equivalents ............................................. 21,832 (448,827)
Cash and cash equivalents at beginning of period ................................................. 455,674 557,533
----------- -----------
Cash and cash equivalents at end of period ....................................................... $ 477,506 $ 108,706
=========== ===========
</TABLE>
The accompanying notes are an integral part of the consolidated
financial statements.
6
<PAGE>
SUPPLEMENTAL NOTES TO FINANCIAL STATEMENTS
The unaudited interim consolidated financial statements and related
notes have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission. Accordingly, certain information and footnote
disclosures normally included in financial statements prepared in accordance
with generally accepted accounting principles have been omitted pursuant to such
rules and regulations. The accompanying unaudited interim consolidated financial
statements and related notes should be read in conjunction with the consolidated
financial statements and notes thereto included in the Company's most recent
Form 10-K covering the year ended December 31, 1999.
The information furnished reflects, in the opinion of the management of
Arrhythmia Research Technology, Inc. ("ART"), all adjustments necessary for a
fair presentation of the financial results for the interim period presented.
Interim results are subject to year-end adjustments and audit by
independent certified public accountants.
INVENTORIES:
Inventories consist of the following as of:
<TABLE>
<CAPTION>
MARCH 31, DECEMBER 31,
2000 1999
---------- ----------
<S> <C> <C>
Raw materials ............................. $ 253,150 $ 252,237
Work-in-process ........................... 228,192 233,966
Finished goods ............................ 1,176,162 1,054,814
---------- ----------
Total ................................ 1,657,504 1,541,017
Allowance for slow-moving inventories ..... ( 456,300) ( 458,500)
---------- ----------
Total ................................ $1,201,204 $1,082,517
========== ==========
</TABLE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
LIQUIDITY AND CAPITAL RESOURCES
At March 31, 2000, the Company had working capital of approximately
$2,197,000. At December 31, 1999, the Company had working capital of
approximately $2,174,000. The Company has negotiated a $1,000,000 working
capital line of credit with a bank, collateralized by accounts receivable and
inventory of ART and Micron Products Inc., which bears interest at prime. The
working capital line of credit had no outstanding balance at March 31, 2000.
The Company's lines of credit are its primary source of operating funds and
liquidity.
In April 2000, the Company renewed a private bond placement, which
was due to mature in May 2000. The bonds in the amount of $600,000 are
subordinated to the bank, carry a 11% interest rate and mature May 31, 2002.
The bondholders also received an extension for outstanding warrants to
acquire 279,000 shares of ART stock at $1.50 per share.
Capital expenditures during the first three months of 2000 were
approximately $141,000 compared to $159,000 in 1999. This decrease can be
attributed to the Micron division. Capital expenditures are expected to
remain lower for the second and third quarter. Normal capital expenditures
are funded from operating cash flows.
RESULTS OF OPERATIONS
REVENUES for the first quarter ended March 31, 2000 were
$2,543,826, compared to $2,441,683 for the first quarter ended March 31,
1999. The sales mix for the Company continues with ECG sensors making up a
greater portion of sales and the related cost of sales. Revenues from sales
of electrocardiographic ("ECG") sensors increased 10% for the quarter ended
March 31, 2000.
Until 1996, ART acted as the exclusive distributor of
electrophysiology ("EP") products under its contract with their manufacturer,
Prucka Engineering, Inc. Prucka was recently acquired by a major corporation
and the new owner has requested ART to restructure its contract. Negotiations
have started on a possible buyout by Prucka of future commissions.
7
<PAGE>
Domestic and foreign sales for the first quarter are as follows:
<TABLE>
<CAPTION>
FIRST QUARTER
-------------
2000 % 1999 %
----------- ----------- ----------- -----------
<S> <C> <C> <C> <C>
Domestic ......... $ 791,588 30 $ 1,268,555 52
Foreign .......... 1,752,238 70 1,173,128 48
----------- ----------- ----------- -----------
Total ............ $ 2,543,826 100 $ 2,441,683 100
=========== =========== =========== ===========
</TABLE>
COST OF SALES decreased by 3.0% for the quarter ended March 31,
2000, as compared to the same period in 1999 due to the full impact of
production improvements and cost reductions for Micron Products started in
1999.
SELLING AND MARKETING expenses increased from 2.9% to 4.2% of sales
during the first quarter ended March 31, 2000. Several trial marketing
programs, which produced minimal sales, have now been curtailed so the
remainder of 2000 should return to 1999 levels.
GENERAL AND ADMINISTRATIVE expenses decreased $14,000 in the first
quarter ended March 31, 2000, as compared to 1998. The primary components of
general and administrative expenses are salaries and related payroll taxes
and benefits, environmental monitoring expenses, professional fees, and
insurance costs. General and administrative expenses are expected to continue
at this level for the remainder of the year.
RESEARCH AND DEVELOPMENT expenses increased $8,000 for the first
quarter ended March 31, 2000, as compared to the same period in 1999.
SAFE HARBOR UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.
Any forward looking statements made herein are based on current
expectations of the Company that involves a number of risks and uncertainties
and should not be considered as guarantees of future performance. These
statements are made under the Safe Harbor Provisions of the Private
Securities Litigation Reform Act of 1995. The factors that could cause actual
results to differ materially include: interruptions or cancellation of
existing contracts, impact of competitive products and pricing, product
demand and market acceptance risks, the presence of competitors with greater
financial resources than the Company, product development and
commercialization risks and an inability to arrange additional debt or equity
financing.
8
<PAGE>
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS - In March 2000, Astro-Med, Inc. ("Astro-Med")
filed suit against ART in Superior Court of Kent County, Rhode Island (the
"RI Litigation") alleging breach of contract, book account and unjust
enrichment. The suit is based upon the purchase by ART of the K-3 hemodynamic
monitoring system product line from Astro-Med. In April 1997, ART and
Astro-Med entered into an Asset Purchase Agreement (the "Agreement"). In
September 1999 ART ceased to make payments to Astro-Med pursuant to the
Agreement. Astro-Med claims that ART is indebted to Astro-Med in the
principal amount of $178,279.06, plus interest and late fees.
ART has removed the RI Litigation to the United States District Court for the
District of Rhode Island and has filed a motion to dismiss. ART will
vigorously defend its position on the substantive allegations raised by
Astro-Med.
ITEM 2. CHANGES IN SECURITIES - NONE
ITEM 3. DEFAULTS UPON SENIOR SECURITIES - NONE
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS - NONE
ITEM 5. OTHER INFORMATION - NONE
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K - NONE
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ARRHYTHMIA RESEARCH TECHNOLOGY, INC.
------------------------------------
/s/ Anthony A. Cetrone,
President, Micron Products Inc.
Chairman of the Board
May 10, 2000
9
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-START> JAN-01-2000
<PERIOD-END> MAR-31-2000
<CASH> 478
<SECURITIES> 0
<RECEIVABLES> 1,688
<ALLOWANCES> 83
<INVENTORY> 1,201
<CURRENT-ASSETS> 3,689
<PP&E> 7,676
<DEPRECIATION> 3,888
<TOTAL-ASSETS> 9,877
<CURRENT-LIABILITIES> 1,492
<BONDS> 723
0
0
<COMMON> 87
<OTHER-SE> 8,268
<TOTAL-LIABILITY-AND-EQUITY> 9,877
<SALES> 2,544
<TOTAL-REVENUES> 2,544
<CGS> 1,677
<TOTAL-COSTS> 678
<OTHER-EXPENSES> 28
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 7
<INCOME-PRETAX> 154
<INCOME-TAX> 52
<INCOME-CONTINUING> 101
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 101
<EPS-BASIC> 0.03
<EPS-DILUTED> 0.03
</TABLE>
